CureVac NV (CVAC)vsRevolution Medicines Inc (RVMD)
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
CureVac NV generates 9434% more annual revenue ($70.74M vs $742,000). CVAC leads profitability with a 182.1% profit margin vs 0.0%. CVAC earns a higher WallStSmart Score of 56/100 (C).
CVAC
Buy56
out of 100
Grade: C
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.3%
Fair Value
$13.04
Current Price
$4.66
$8.38 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 89.0%
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CVAC profiles as a declining stock while RVMD is a value play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
CVAC is growing revenue faster at -89.0% — sustainability is the question.
CVAC generates stronger free cash flow (30M), providing more financial flexibility.
Bottom Line
CVAC scores higher overall (56/100 vs 24/100), backed by strong 182.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?